We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
Beovu showed it was non-inferior in terms of improvements in visual acuity for patients compared with rival treatment aflibercept. "Novartis Sees Blockbuster Potential in Eye-Disease Drug -- Update," on Oct. 8 at GMT 1216, misstated that Beovu achieved superior visual improvements compared with aflibercept in the fifth paragraph. The error also appeared in an earlier version of the story, "Novartis: US FDA Approves Eye-Disease Treatment Beovu," at 0535 GMT the same day.
(END) Dow Jones Newswires
October 09, 2019 13:23 ET (17:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
